|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KLK3 |
Gene summary for KLK3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KLK3 | Gene ID | 354 |
| Gene name | kallikrein related peptidase 3 | |
| Gene Alias | APS | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | P07288 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 354 | KLK3 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 7.72e-07 | 2.48e-02 | -0.2126 |
| 354 | KLK3 | 047563_1562-all-cells | Human | Prostate | BPH | 1.97e-28 | 7.77e-01 | 0.0791 |
| 354 | KLK3 | 048752_1579-all-cells | Human | Prostate | BPH | 3.96e-90 | 1.18e+00 | 0.1008 |
| 354 | KLK3 | 052097_1595-all-cells | Human | Prostate | BPH | 6.48e-16 | 4.50e-01 | 0.0972 |
| 354 | KLK3 | 052099_1652-all-cells | Human | Prostate | BPH | 1.54e-70 | 1.06e+00 | 0.1038 |
| 354 | KLK3 | Dong_P4 | Human | Prostate | Tumor | 1.92e-17 | 7.55e-01 | 0.0292 |
| 354 | KLK3 | Dong_P5 | Human | Prostate | Tumor | 4.52e-12 | -2.19e-01 | 0.053 |
| 354 | KLK3 | P7 | Human | Prostate | Tumor | 2.01e-17 | 1.32e+00 | -0.1025 |
| 354 | KLK3 | P10 | Human | Prostate | Tumor | 6.88e-12 | 1.07e+00 | -0.0902 |
| 354 | KLK3 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 2.16e-03 | 8.72e-01 | 0.1531 |
| 354 | KLK3 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.96e-06 | 6.76e-01 | 0.1621 |
| 354 | KLK3 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 1.91e-02 | 7.31e-01 | 0.1622 |
| 354 | KLK3 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 4.25e-03 | 4.16e-01 | 0.1575 |
| 354 | KLK3 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.25e-03 | 2.93e-01 | 0.1545 |
| 354 | KLK3 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 1.87e-02 | 3.76e-01 | 0.1569 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00516049 | Prostate | BPH | protein maturation | 80/3107 | 294/18723 | 2.64e-06 | 4.23e-05 | 80 |
| GO:00164855 | Prostate | BPH | protein processing | 62/3107 | 225/18723 | 2.22e-05 | 2.67e-04 | 62 |
| GO:19013424 | Prostate | BPH | regulation of vasculature development | 78/3107 | 348/18723 | 2.76e-03 | 1.46e-02 | 78 |
| GO:00457654 | Prostate | BPH | regulation of angiogenesis | 76/3107 | 342/18723 | 3.90e-03 | 1.95e-02 | 76 |
| GO:005160415 | Prostate | Tumor | protein maturation | 81/3246 | 294/18723 | 7.58e-06 | 1.13e-04 | 81 |
| GO:001648512 | Prostate | Tumor | protein processing | 63/3246 | 225/18723 | 4.40e-05 | 4.98e-04 | 63 |
| GO:190134212 | Prostate | Tumor | regulation of vasculature development | 79/3246 | 348/18723 | 5.84e-03 | 2.71e-02 | 79 |
| GO:004576512 | Prostate | Tumor | regulation of angiogenesis | 77/3246 | 342/18723 | 7.92e-03 | 3.52e-02 | 77 |
| GO:00028316 | Prostate | Tumor | regulation of response to biotic stimulus | 74/3246 | 327/18723 | 8.03e-03 | 3.54e-02 | 74 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa052159 | Prostate | BPH | Prostate cancer | 48/1718 | 97/8465 | 1.08e-10 | 1.87e-09 | 1.16e-09 | 48 |
| hsa0521514 | Prostate | BPH | Prostate cancer | 48/1718 | 97/8465 | 1.08e-10 | 1.87e-09 | 1.16e-09 | 48 |
| hsa0521523 | Prostate | Tumor | Prostate cancer | 48/1791 | 97/8465 | 4.86e-10 | 8.93e-09 | 5.54e-09 | 48 |
| hsa0521533 | Prostate | Tumor | Prostate cancer | 48/1791 | 97/8465 | 4.86e-10 | 8.93e-09 | 5.54e-09 | 48 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KLK3 | SNV | Missense_Mutation | c.626N>A | p.Cys209Tyr | p.C209Y | P07288 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| KLK3 | SNV | Missense_Mutation | rs182759459 | c.391N>A | p.Glu131Lys | p.E131K | P07288 | protein_coding | tolerated(0.75) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KLK3 | SNV | Missense_Mutation | novel | c.507G>C | p.Lys169Asn | p.K169N | P07288 | protein_coding | tolerated(0.07) | benign(0.013) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KLK3 | SNV | Missense_Mutation | rs373661565 | c.398N>T | p.Thr133Met | p.T133M | P07288 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AY-4070-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fu | PD |
| KLK3 | SNV | Missense_Mutation | rs372901531 | c.712G>A | p.Glu238Lys | p.E238K | P07288 | protein_coding | tolerated(0.66) | benign(0.001) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| KLK3 | SNV | Missense_Mutation | c.49N>A | p.Ala17Thr | p.A17T | P07288 | protein_coding | tolerated(0.06) | probably_damaging(0.944) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KLK3 | SNV | Missense_Mutation | novel | c.507N>T | p.Lys169Asn | p.K169N | P07288 | protein_coding | tolerated(0.07) | benign(0.013) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KLK3 | SNV | Missense_Mutation | rs200116262 | c.689N>A | p.Gly230Asp | p.G230D | P07288 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KLK3 | SNV | Missense_Mutation | c.96G>T | p.Glu32Asp | p.E32D | P07288 | protein_coding | tolerated(0.06) | benign(0.111) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| KLK3 | SNV | Missense_Mutation | novel | c.422N>C | p.Leu141Pro | p.L141P | P07288 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 354 | KLK3 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | CHEMBL1201837 | ECALLANTIDE | |
| 354 | KLK3 | DRUGGABLE GENOME, PROTEASE, ENZYME | SELENIUM | 16648561 | ||
| 354 | KLK3 | DRUGGABLE GENOME, PROTEASE, ENZYME | BACILLUS CALMETTE-GUERIN | 11025701 | ||
| 354 | KLK3 | DRUGGABLE GENOME, PROTEASE, ENZYME | Rilimogene galvacirepvec | |||
| 354 | KLK3 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | CHEMBL1201619 | APROTININ | |
| 354 | KLK3 | DRUGGABLE GENOME, PROTEASE, ENZYME | IMMUNOCONJUGATE | 7523704,10368631 | ||
| 354 | KLK3 | DRUGGABLE GENOME, PROTEASE, ENZYME | PROGESTIN | PROGESTERONE | 9052414 | |
| 354 | KLK3 | DRUGGABLE GENOME, PROTEASE, ENZYME | ABARELIX | ABARELIX | 11342922 | |
| 354 | KLK3 | DRUGGABLE GENOME, PROTEASE, ENZYME | MIFEPRISTONE | MIFEPRISTONE | 9052414 | |
| 354 | KLK3 | DRUGGABLE GENOME, PROTEASE, ENZYME | RHENIUM-186 HYDROXYETHYLIDENE DIPHOSPHONATE | 12087455 |
| Page: 1 2 3 4 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |